MicroRNA‐1307‐3p contributes to breast cancer progression through PRM2

Abstract Background Despite advances in screening and therapy, breast cancer (BC) remains the predominant cancer in women globally. Dysregulation of microRNAs (miRNAs) is pivotal in carcinogenesis across various cancers, including BC. Evidence indicates that miR‐1307‐3p is upregulated in BC tumors,...

Full description

Saved in:
Bibliographic Details
Main Authors: José Roberto Estupiñan‐Jiménez, Valeria Villarreal‐García, Vianey Gonzalez‐Villasana, Pablo E. Vivas‐Mejia, Jose Manuel Vazquez‐Guillen, Patricio Adrián Zapata‐Morin, Marienid Flores‐Colón, Claudia Altamirano‐Torres, Ezequiel Viveros‐Valdez, Cristina Ivan, Mohammed H. Rashed, Recep Bayraktar, Cristina Rodríguez‐Padilla, Gabriel Lopez‐Berestein, Diana Resendez‐Perez
Format: Article
Language:English
Published: Wiley 2024-11-01
Series:Thoracic Cancer
Subjects:
Online Access:https://doi.org/10.1111/1759-7714.15460
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850194450694799360
author José Roberto Estupiñan‐Jiménez
Valeria Villarreal‐García
Vianey Gonzalez‐Villasana
Pablo E. Vivas‐Mejia
Jose Manuel Vazquez‐Guillen
Patricio Adrián Zapata‐Morin
Marienid Flores‐Colón
Claudia Altamirano‐Torres
Ezequiel Viveros‐Valdez
Cristina Ivan
Mohammed H. Rashed
Recep Bayraktar
Cristina Rodríguez‐Padilla
Gabriel Lopez‐Berestein
Diana Resendez‐Perez
author_facet José Roberto Estupiñan‐Jiménez
Valeria Villarreal‐García
Vianey Gonzalez‐Villasana
Pablo E. Vivas‐Mejia
Jose Manuel Vazquez‐Guillen
Patricio Adrián Zapata‐Morin
Marienid Flores‐Colón
Claudia Altamirano‐Torres
Ezequiel Viveros‐Valdez
Cristina Ivan
Mohammed H. Rashed
Recep Bayraktar
Cristina Rodríguez‐Padilla
Gabriel Lopez‐Berestein
Diana Resendez‐Perez
author_sort José Roberto Estupiñan‐Jiménez
collection DOAJ
description Abstract Background Despite advances in screening and therapy, breast cancer (BC) remains the predominant cancer in women globally. Dysregulation of microRNAs (miRNAs) is pivotal in carcinogenesis across various cancers, including BC. Evidence indicates that miR‐1307‐3p is upregulated in BC tumors, yet its target genes are not fully elucidated. This study aimed to explore how miR‐1307‐3p regulates BC proliferation, migration, invasion, and angiogenesis and to identify potential target genes. Methods Basal miR‐1307‐3p levels were quantified in BC cell lines MDA‐MB‐231 and MCF‐7, as well as MCF‐10A using quantitative real‐time reverse transcription‐PCR (RT‐qPCR). The impact of miR‐1307‐3p inhibition on BC cell proliferation, migration, invasion, and angiogenesis was assessed. Nine miRNA‐target prediction databases identified potential miR‐1307‐3p targets. Target expression was validated using RT‐qPCR, Western blot, and dual‐luciferase reporter assays. MiR‐1307‐3p was overexpressed in MDA‐MB‐231 and MCF‐7 compared to MCF‐10A. Results Inhibiting miR‐1307‐3p significantly reduced BC cell proliferation, migration, invasion, and angiogenesis. Bioinformatics analysis identified 17 potential miR‐1307‐3p targets, with protamine 2 (PRM2) overexpression confirmed via Western blot and dual‐luciferase assays. Conclusion MiR‐1307‐3p overexpression in BC promotes proliferation, migration, invasion, and angiogenesis. PRM2 emerges as a novel miR‐1307‐3p target in BC.
format Article
id doaj-art-a1b3346bdbed4eaaa2d23f4f940cb712
institution OA Journals
issn 1759-7706
1759-7714
language English
publishDate 2024-11-01
publisher Wiley
record_format Article
series Thoracic Cancer
spelling doaj-art-a1b3346bdbed4eaaa2d23f4f940cb7122025-08-20T02:13:59ZengWileyThoracic Cancer1759-77061759-77142024-11-0115322298230810.1111/1759-7714.15460MicroRNA‐1307‐3p contributes to breast cancer progression through PRM2José Roberto Estupiñan‐Jiménez0Valeria Villarreal‐García1Vianey Gonzalez‐Villasana2Pablo E. Vivas‐Mejia3Jose Manuel Vazquez‐Guillen4Patricio Adrián Zapata‐Morin5Marienid Flores‐Colón6Claudia Altamirano‐Torres7Ezequiel Viveros‐Valdez8Cristina Ivan9Mohammed H. Rashed10Recep Bayraktar11Cristina Rodríguez‐Padilla12Gabriel Lopez‐Berestein13Diana Resendez‐Perez14Departmento de Biología Celular y Genética, Facultad de Ciencias Biológicas Universidad Autónoma de Nuevo León San Nicolás de los Garza MexicoDepartmento de Biología Celular y Genética, Facultad de Ciencias Biológicas Universidad Autónoma de Nuevo León San Nicolás de los Garza MexicoDepartmento de Biología Celular y Genética, Facultad de Ciencias Biológicas Universidad Autónoma de Nuevo León San Nicolás de los Garza MexicoDepartment of Biochemistry, Medical Sciences Campus University of Puerto Rico San Juan Puerto RicoLaboratorio de Inmunología y Virología, Facultad de Ciencias Biológicas Universidad Autónoma de Nuevo León San Nicolás de los Garza MexicoLaboratorio de Micología y Fitopatología, Unidad de Manipulación Genética, Facultad de Ciencias Biológicas Universidad Autónoma de Nuevo León San Nicolás de los Garza MexicoDepartment of Biochemistry, Medical Sciences Campus University of Puerto Rico San Juan Puerto RicoDepartmento de Biología Celular y Genética, Facultad de Ciencias Biológicas Universidad Autónoma de Nuevo León San Nicolás de los Garza MexicoDepartamento de Química, Facultad de Ciencias Biológicas Universidad Autónoma de Nuevo León San Nicolás de los Garza MexicoDepartment of Experimental Therapeutics The University of Texas MD Anderson Cancer Center Houston Texas USAClinical Pharmacy Department, Faculty of Pharmacy (Boys) Al‐Azhar University Cairo EgyptDepartment of Translational Molecular Pathology The University of Texas MD Anderson Cancer Center Houston Texas USALaboratorio de Inmunología y Virología, Facultad de Ciencias Biológicas Universidad Autónoma de Nuevo León San Nicolás de los Garza MexicoDepartment of Experimental Therapeutics The University of Texas MD Anderson Cancer Center Houston Texas USADepartmento de Biología Celular y Genética, Facultad de Ciencias Biológicas Universidad Autónoma de Nuevo León San Nicolás de los Garza MexicoAbstract Background Despite advances in screening and therapy, breast cancer (BC) remains the predominant cancer in women globally. Dysregulation of microRNAs (miRNAs) is pivotal in carcinogenesis across various cancers, including BC. Evidence indicates that miR‐1307‐3p is upregulated in BC tumors, yet its target genes are not fully elucidated. This study aimed to explore how miR‐1307‐3p regulates BC proliferation, migration, invasion, and angiogenesis and to identify potential target genes. Methods Basal miR‐1307‐3p levels were quantified in BC cell lines MDA‐MB‐231 and MCF‐7, as well as MCF‐10A using quantitative real‐time reverse transcription‐PCR (RT‐qPCR). The impact of miR‐1307‐3p inhibition on BC cell proliferation, migration, invasion, and angiogenesis was assessed. Nine miRNA‐target prediction databases identified potential miR‐1307‐3p targets. Target expression was validated using RT‐qPCR, Western blot, and dual‐luciferase reporter assays. MiR‐1307‐3p was overexpressed in MDA‐MB‐231 and MCF‐7 compared to MCF‐10A. Results Inhibiting miR‐1307‐3p significantly reduced BC cell proliferation, migration, invasion, and angiogenesis. Bioinformatics analysis identified 17 potential miR‐1307‐3p targets, with protamine 2 (PRM2) overexpression confirmed via Western blot and dual‐luciferase assays. Conclusion MiR‐1307‐3p overexpression in BC promotes proliferation, migration, invasion, and angiogenesis. PRM2 emerges as a novel miR‐1307‐3p target in BC.https://doi.org/10.1111/1759-7714.15460breast cancercancer progressionmicroRNAsmiR‐1307‐3pprotamine 2
spellingShingle José Roberto Estupiñan‐Jiménez
Valeria Villarreal‐García
Vianey Gonzalez‐Villasana
Pablo E. Vivas‐Mejia
Jose Manuel Vazquez‐Guillen
Patricio Adrián Zapata‐Morin
Marienid Flores‐Colón
Claudia Altamirano‐Torres
Ezequiel Viveros‐Valdez
Cristina Ivan
Mohammed H. Rashed
Recep Bayraktar
Cristina Rodríguez‐Padilla
Gabriel Lopez‐Berestein
Diana Resendez‐Perez
MicroRNA‐1307‐3p contributes to breast cancer progression through PRM2
Thoracic Cancer
breast cancer
cancer progression
microRNAs
miR‐1307‐3p
protamine 2
title MicroRNA‐1307‐3p contributes to breast cancer progression through PRM2
title_full MicroRNA‐1307‐3p contributes to breast cancer progression through PRM2
title_fullStr MicroRNA‐1307‐3p contributes to breast cancer progression through PRM2
title_full_unstemmed MicroRNA‐1307‐3p contributes to breast cancer progression through PRM2
title_short MicroRNA‐1307‐3p contributes to breast cancer progression through PRM2
title_sort microrna 1307 3p contributes to breast cancer progression through prm2
topic breast cancer
cancer progression
microRNAs
miR‐1307‐3p
protamine 2
url https://doi.org/10.1111/1759-7714.15460
work_keys_str_mv AT joserobertoestupinanjimenez microrna13073pcontributestobreastcancerprogressionthroughprm2
AT valeriavillarrealgarcia microrna13073pcontributestobreastcancerprogressionthroughprm2
AT vianeygonzalezvillasana microrna13073pcontributestobreastcancerprogressionthroughprm2
AT pabloevivasmejia microrna13073pcontributestobreastcancerprogressionthroughprm2
AT josemanuelvazquezguillen microrna13073pcontributestobreastcancerprogressionthroughprm2
AT patricioadrianzapatamorin microrna13073pcontributestobreastcancerprogressionthroughprm2
AT marienidflorescolon microrna13073pcontributestobreastcancerprogressionthroughprm2
AT claudiaaltamiranotorres microrna13073pcontributestobreastcancerprogressionthroughprm2
AT ezequielviverosvaldez microrna13073pcontributestobreastcancerprogressionthroughprm2
AT cristinaivan microrna13073pcontributestobreastcancerprogressionthroughprm2
AT mohammedhrashed microrna13073pcontributestobreastcancerprogressionthroughprm2
AT recepbayraktar microrna13073pcontributestobreastcancerprogressionthroughprm2
AT cristinarodriguezpadilla microrna13073pcontributestobreastcancerprogressionthroughprm2
AT gabriellopezberestein microrna13073pcontributestobreastcancerprogressionthroughprm2
AT dianaresendezperez microrna13073pcontributestobreastcancerprogressionthroughprm2